NRC-IRAP's Canadian HIV Technology Development Program (CHTD)
On April 1st 2011, NRC-IRAP launched the Canadian HIV Technology Development (CHTD) Program which represents a significant Canadian contribution to global efforts to develop a safe, effective, affordable and globally accessible HIV vaccine.
Over the next five years, the CHTD Program will receive funding through Industry Canada, in relation to the Canadian HIV Vaccine Initiative (CHVI), a collaborative effort between the Government of Canada and the Bill & Melinda Gates Foundation. NRC-IRAP, with its extensive and established networks within the Biomedical industry in Canada, is well positioned to successfully deliver financial assistance and advisory services for HIV-related projects for which this funding has been designated.
The objective of the NRC-IRAP CHTD Program is to actively encourage and support the participation of small- and medium-sized enterprises in the development of an HIV vaccine and other technologies related to the prevention, treatment and diagnosis of HIV.
If your firm is incorporated, has 500 or fewer employees and is currently involved in some research or technology related to HIV you could be eligible to receive assistance from NRC-IRAP through our CHTD Program.
For more information on the eligibility criteria for financial assistance or how to reach an NRC-IRAP Industrial Technology Advisor (ITA) located in your area, please call our toll-free number at 1-877-994-4727.
NRC-IRAP helps firms to develop technologies and successfully commercialize them in a global marketplace. We do this by providing technical and business advisory services and financial assistance to the small- and medium-sized enterprises (SMEs) we serve.
- Date modified: